7-[(E)-5-[4'-[(E)-5-(3,3-dimethyloxiran-2-yl)-3-methylpent-2-enoxy]-5,5-dimethylspiro[1,3-dioxolane-2,7'-furo[3,2-g]chromene]-4-yl]-3-methylpent-2-enoxy]chromen-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-[(E)-5-[4'-[(E)-5-(3,3-dimethyloxiran-2-yl)-3-methylpent-2-enoxy]-5,5-dimethylspiro[1,3-dioxolane-2,7'-furo[3,2-g]chromene]-4-yl]-3-methylpent-2-enoxy]chromen-2-one
• 化学式: C₄₀H₄₄O₉
• 分子量: 668.8
• InChiKey: XAKXAFWXIUEQSQ-ZZZAPRPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  49
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  98.1
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• ANTI-FIRST-PASS EFFECT COMPOUNDS
  申请人：HARRIS W. James

  公开号：US20070244188A1

  公开（公告）日：2007-10-18

  Compositions, methods, etc. for addressing the first-pass effect.
• Tacrolimus Combination Products
  申请人：Ranklove Lisbet Bonlokke

  公开号：US20090011013A1

  公开（公告）日：2009-01-08

  The present invention relates to a pharmaceutical composition comprising tacrolimus or an analogue thereof and a substance being a substrate for CYP3A4 and/or P-glycoprotein, oral solid dosage forms comprising the pharmaceutical composition such as tablets, methods for preparing the pharmaceutical composition and oral dosage forms and use of the pharmaceutical composition for preparing a medicament. The substance being a substrate for CYP3A4 and/or P-glycoprotein is preferably cyclosporine A. The invention further relates to treatment of a patient in need thereof by coadministration of the combination according to the invention. In a further aspect, the invention relates to the above combination further comprising a CYP3A4 inhibitor compound, preferably a compound naturally occurring in citrus juice, for example grapefruit juice, preferably a spiro ortho ester compound.
• US7230027B2
  申请人：——

  公开号：US7230027B2

  公开（公告）日：2007-06-12
• US7378534B2
  申请人：——

  公开号：US7378534B2

  公开（公告）日：2008-05-27
• US7514572B2
  申请人：——

  公开号：US7514572B2

  公开（公告）日：2009-04-07